Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

Gökçel, Adnan; Gümürdülü, Yüksel; Karakose, Hatice; Ertorer, Melek Eda; Tanaci, Nedret; Tütüncü, Neslihan Başçıl; Güvener, Nilgün

doi:10.1046/j.1463-1326.2002.00181.x

Cited by 147 publications

(138 citation statements)

References 38 publications

Supporting

Mentioning

105

Contrasting

Unclassified

Order By: Relevance

“…A randomized trial in 150 women with BMI 430 kg/m 2 (of whom 15 had type 2 diabetes) evaluated sibutramine, metformin or orlistat for 6 months. 80 Weight, waist and BMI were reduced in all groups (Po0.0001). Small 7-month studies in nondiabetic overweight (BMI 428 kg/m 2 ) 81 or morbidly obese subjects (mean BMI 43 kg/m 2 ) 82 demonstrated decreases in body weight with metformin, although only the latter study demonstrated a reduction in waist circumference.…”

Section: Effects Of Metformin On Body Weight In Nondiabetic Patientsmentioning

confidence: 85%

“…[79][80][81][82] The first Biguanides and Prevention of the Risks in Obesity study 1 enrolled 324 patients with abdominal obesity (waist-hip ratio X0.95 in men and X0.80 in women) in order to recruit a trial population containing a high prevalence of insulin resistance. 79 Subjects were also free of cardiovascular disease and diabetes at baseline.…”

Section: Effects Of Metformin On Body Weight In Nondiabetic Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Metformin and body weight

2007

View full text Add to dashboard Cite

Most patients with type 2 diabetes are overweight or obese, overweight or obesity increases the risk of developing type 2 diabetes and obesity per se is strongly associated with multiple cardiometabolic risk factors. However, many antidiabetic treatments increase body weight. The oral antidiabetic agent, metformin, has been evaluated in hundreds of clinical studies in diverse patient populations during approximately five decades of clinical use. This review summarizes the effects of metformin on body weight, with special reference to studies of longer duration (X6 months) as both diabetes and obesity are long-term conditions. Approximately half of studies in drug-naive type 2 diabetic patients demonstrated significant weight loss with metformin compared with baseline or comparator drugs, although pooled analyses have suggested no significant effect versus placebo. Similarly, metformin has been shown to induce weight loss in obese nondiabetic populations, although studies of long duration in this population are scarce. Metformin does appear to mitigate the adverse effects of insulin on body weight. The weight-neutral or weight-sparing effects of metformin constitute a therapeutic advantage in diabetes management where other first-line oral antidiabetic treatments often promote clinically significant weight gain.

show abstract

Section: Effects Of Metformin On Body Weight In Nondiabetic Patientsmentioning

confidence: 85%

Section: Effects Of Metformin On Body Weight In Nondiabetic Patientsmentioning

confidence: 99%

Metformin and body weight

2007

View full text Add to dashboard Cite

show abstract

“…Treatment with metformin can also be considered, especially in those at risk of diabetes as prevention of both weight gain (ADOPT study) and diabetes (PPP study), however further research is needed (Gokcel et al, 2002).…”

Section: Pharmacological and Surgical Treatment Of Obesity In Postmenmentioning

confidence: 99%

Ovarian function and obesity—Interrelationship, impact on women's reproductive lifespan and treatment options

Rachoń

Teede

2010

Molecular and Cellular Endocrinology

125

View full text Add to dashboard Cite

Insulin resistance (IR) is a consequence of obesity, and in women it is often inextricably linked with ovarian function leading to clinical reproductive manifestations such as early menarche onset, subfertility and polycystic ovary syndrome (PCOS). Likewise, the dramatic fall in oestrogen production after menopause may contribute to weight gain and changes in adipose tissue distribution.Overall, women who are obese, especially those with reproductive complications including PCOS, have been identified as specific high risk subgroups for further progression through to prediabetes, type 2 diabetes mellitus (T2DM) and potentially cardiovascular disease (CVD). This review focuses on the interrelationship between the ovarian function and obesity as well as its treatment strategies.

show abstract

“…12 Previous studies have confirmed the efficacy of orlistat in weight reduction, with improvement in cardiovascular risk factors among obese subjects. [12][13][14] Generally, orlistat treatment is associated with significant improvement in the insulin sensitivity. 14,15 On the other hand, it has been demonstrated that metformin, an antihyperglycemic agent, decreases hyperinsulinemia and insulin resistance, leading to decreased adiposity in obese and non-insulin-dependent diabetes mellitus.…”

Section: Introductionmentioning

confidence: 99%

“…[12][13][14] Generally, orlistat treatment is associated with significant improvement in the insulin sensitivity. 14,15 On the other hand, it has been demonstrated that metformin, an antihyperglycemic agent, decreases hyperinsulinemia and insulin resistance, leading to decreased adiposity in obese and non-insulin-dependent diabetes mellitus. [16][17][18] Some investigators have suggested that greater weight loss might be achieved by combining the above-mentioned antiobesity drugs, 11,19,20 as they have different mechanisms of action.…”

Section: Introductionmentioning

confidence: 99%

Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women

et al. 2004

View full text Add to dashboard Cite

BACKGROUND AND AIM:Orlistat and metformin are the currently used drugs for weight loss. We aimed to compare the effect of orlistat and orlistat plus metformin combination therapy on weight loss and insulin resistance in obese women. PATIENTS AND METHODS:In all, 57 obese women (body mass index Z30 kg/m 2 and normal glucose tolerance) were included. All subjects took the same content and caloric diet therapy during the study. After a month of diet period, each individual was randomly assigned to receive 360 mg orlistat per day (group 1; n ¼ 30) or 360 mg orlistat plus 1700 mg metformin per day (group 2; n ¼ 27) during the next 3 months. Body weight and insulin resistance by the homeostasis model assessment model (HOMA-IR) was measured at baseline, first month and fourth month. RESULTS: The mean weight loss in groups 1 and 2 was 1.3670.8 kg (1.470.7%) and 1.1170.7 kg (1.170.7%) from baseline to first month; 4.872.9 kg (5.2873.0%) and 5.7772.5 kg (6.1772.9%) from first month to fourth month. Body weight was decreased in groups 1 (Po 0.001) and 2 (Po 0.001), but there was no statistically significant difference between groups. Change of HOMA-IR in groups 1 and 2 was 0.4170.4 (14.9710.1%) and 0.2370.7 (8.16712.3%) from baseline to first month; 0.4970.77 (22.0726%) and 0.9570.88 (34.8729.1%) from first month to fourth month. HOMA-IR value was decreased in groups 1 (Po 0.001) and 2 (Po 0.001) but was not different between groups during the study period. CONCLUSIONS: Combination of orlistat with metformin did not result in an additional effect on weight loss and insulin resistance when compared to orlistat alone in our study. However, new studies which have more sample sizes and the longer study period are necessary for this purpose.

show abstract

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

Cited by 147 publications

References 38 publications

Metformin and body weight

Metformin and body weight

Ovarian function and obesity—Interrelationship, impact on women's reproductive lifespan and treatment options

Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women

Contact Info

Product

Resources

About